菜单
Search and analyze patents including FTO (Freedom to Operate) analysis, patent landscape mapping, and competitive IP intelligence. Keywords: patent, FTO, freedom to operate, IP, intellectual property
用 Codex 或 Claude 帮你安装 复制这段 Prompt，粘贴到 Codex、Claude 或其他助手里，让它检查 Skill 页面并帮你完成安装。
基于 SOC 职业分类
| name | patent-search |
| description | Search and analyze patents including FTO (Freedom to Operate) analysis, patent landscape mapping, and competitive IP intelligence. Keywords: patent, FTO, freedom to operate, IP, intellectual property |
| category | Patent Analysis |
| tags | ["patent","fto","ip","landscape","claims"] |
| version | 1.0.0 |
| author | Drug Discovery Team |
| dependencies | ["uspto-database","epo-database","wipo-database"] |
Comprehensive patent analysis for drug discovery and IP intelligence.
/patent EGFR inhibitor
/fto "quinazoline EGFR kinase"
/patent-map KRAS G12C
Analyze patent landscape for osimertinib
| Section | Description | Data Source |
|---|---|---|
| Patent Search | Find relevant patents | USPTO, EPO, WIPO |
| Patent Details | Claims, assignees, priority | Patent databases |
| FTO Analysis | Freedom to operate assessment | Claims analysis |
| Landscape Map | Patent clustering and gaps | Aggregated |
| Expiration | Patent expiry dates | Patent databases |
| Family Analysis | Patent family members | Global Dossier |
# Patent Analysis: EGFR Inhibitors
## Executive Summary
**Total Patents**: 3,247 EGFR inhibitor patents found
**Key Patent Families**: 89 unique families
**FTO Risk**: High - crowded landscape with broad claims
## Patent Landscape
| Time Period | Patents | Growth |
|-------------|---------|--------|
| 1990-1999 | 234 | Baseline |
| 2000-2009 | 892 | +281% |
| 2010-2019 | 1,456 | +63% |
| 2020-2024 | 665 | Declining |
## Key Patent Families
### US5747498 (Erlotinib)
| Field | Value |
|-------|-------|
| Assignee | OSI Pharmaceuticals |
| Priority Date | 1994-04-15 |
| Grant Date | 1998-05-05 |
| Expiry | 2018 (expired) |
| Claims | 47 claims |
| Scope | Quinazoline EGFR inhibitors |
### US8017621 (Gefitinib)
| Field | Value |
|-------|-------|
| Assignee | AstraZeneca |
| Priority Date | 1992-03-06 |
| Expiry | 2014 (expired) |
| Scope | Broad EGFR TKI claims |
## FTO Analysis
### High-Risk Patents
| Patent | Risk | Reason |
|--------|------|--------|
| US8772358 | ⚠️ High | 3rd-gen TKI, C797S active |
| US10363010 | ⚠️ High | Broad mutant-selective claims |
| US10588034 | ⚠️ High | Combination therapy claims |
### White Space
| Area | Opportunity | Rationale |
|------|-------------|----------|
| 4th-gen TKI | Low IP pressure | C797S+S1278 niche |
| Allosteric sites | Emerging | Fewer existing claims |
| Bispecific formats | Moderate | Combination IP possible |
## Patent Family Analysis
**Example: Osimertinib (AZD9291)**
| Jurisdiction | Patent | Status | Expiry |
|-------------|--------|--------|--------|
| US | US8772358 | Expired | 2033 |
| EP | EP2378967 | Granted | 2033 |
| JP | JP5958971 | Granted | 2033 |
| CN | CN102822420 | Granted | 2033 |
## Claim Analysis
**US8772358 Claim 1 (Representative):**
A compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of a proliferative disease mediated by EGFR having the T790M mutation...
**Breadth:** Broad - covers mutant-selective EGFR inhibitors
**Enforceability:** High - well-defined structure
**Workaround:** Difficult - covers core scaffold
## Competitive IP Map
| Company | Patent Families | Core Focus |
|----------|-----------------|-------------|
| AstraZeneca | 12 | 3rd-gen TKI, combinations |
| Johnson & Johnson | 8 | Bispecific antibodies |
| Daiichi Sankyo | 6 | ADC conjugates |
| Blueprint Medicines | 4 | 4th-gen TKI |
| Yuhan/Roche | 3 | Lazertinib combinations |
/patent EGFR quinazoline
/patent-search "KRAS G12C inhibitor"
Find all patents for sotorasib
/fto "EGFR TKI scaffold"
/fto-analysis compound.smi
Can I make this compound without infringement?
/patent-map KRAS inhibitors
Map patent landscape for 4th-gen EGFR
Analyze IP gaps in PROTAC EGFR degraders
/patent US8772358 --family
/patent WO2010130291 --global
Show all related patents for osimertinib
# Search patents by keyword
python scripts/patent_search.py "EGFR inhibitor" --output patents.json
# FTO analysis
python scripts/patent_search.py --fto "quinazoline scaffold" --claims
# Patent family lookup
python scripts/patent_search.py --family US8772358
# Landscape mapping
python scripts/patent_search.py --landscape "KRAS G12C" --cluster
# Expiration analysis
python scripts/patent_search.py --expiry "EGFR TKI" --sort-by-date
pip install requests pandas lxml
| Pitfall | Solution |
|---|---|
| Narrow search | Use multiple terms/synonyms |
| Ignoring families | Check global coverage |
| Misreading claims | Claims define scope, not title |
| Overlooked continuations | Check continuation-in-part (CIP) |
| Publication vs. grant | Check granted patent status |
Global drug development pipeline tracking by disease, target, mechanism, or company. Use for competitive intelligence, opportunity identification, and trend analysis. Keywords: pipeline, drug development, clinical trials, R&D tracking, competitive landscape
Structure-based similarity search and scaffold analysis for drug discovery. Use for lead hopping, scaffold morphing, and chemical space exploration. Keywords: similarity search, scaffold hopping, chemical space, fingerprint, Tanimoto
Analyze target competitive landscape including existing drugs, pipeline companies, differentiation opportunities, and market maturity assessment. Keywords: target competition, landscape, differentiation, pipeline analysis, market share
Target safety assessment including known toxicities, essentiality, and off-target concerns. Use for early safety risk evaluation and target selection. Keywords: target safety, toxicity, essential gene, knockout, safety risks
Comprehensive target validation assessing druggability, disease association strength, tractability, and competitive landscape. Use for go/no-go decisions on target selection. Keywords: target validation, druggability, tractability, disease association, genetic validation
ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity) prediction for drug candidates. Use for assessing drug-likeness, PK properties, and safety risks early in drug discovery. Keywords: ADMET, PK, toxicity, drug-likeness, DILI, hERG, bioavailability